A5065864100- Angiogenesis and VEGF in Cancer
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Neutropenia and Cancer Infections
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Renal cell carcinoma treatment
- Cancer, Lipids, and Metabolism
- Cell Adhesion Molecules Research
- Cancer Research and Treatments
- T-cell and B-cell Immunology
- Cancer Treatment and Pharmacology
- Cancer, Stress, Anesthesia, and Immune Response
- Neuroblastoma Research and Treatments
- Immune cells in cancer
- Renal and related cancers
- Colorectal and Anal Carcinomas
- Renal Diseases and Glomerulopathies
- Chemokine receptors and signaling
- Lymphatic System and Diseases
- Hematological disorders and diagnostics
- Reproductive System and Pregnancy
- Pancreatic and Hepatic Oncology Research
University of Perugia
2023
Policlinico San Matteo Fondazione
2007-2017
Istituti di Ricovero e Cura a Carattere Scientifico
2007-2017
University of Pavia
2008-2017
Foundation Center
2011
<i>Objective:</i> The efficacy of bevacizumab in metastatic colorectal cancer (mCRC) could be related not only to its well-known antiangiogenetic properties but also a hypothetical effect on the immune system host. <i>Methods:</i> We enrolled mCRC patients treated with bevacizumab-based first-line therapy. Lymphocyte and dendritic cell subsets were evaluated at baseline, 3rd 6th cycle. clinical was estimated as response rate progression-free survival. Forty healthy...
Dendritic cells (DCs) are the key antigen-presenting controlling initiation of T cell- dependent immune response. Currently, two peripheral blood DC subsets have been identified on basis their CD11c expression. The CD11c-negative (CD11c–) DCs (expressing high levels CD123) designated as lymphoid-derived (DC2), whereas CD11c+/CD123– cells, do identify myeloidderived (DC1). A growing number studies conducted in recent years both quantitative and functional alterations different pathological...
The overall risk of some cancers is increased in patients receiving regular dialysis treatment due to chronic oxidative stress, a weakened immune system and enhanced genomic damage. These could benefit from the same antineoplastic delivered with normal renal function, but better risk/benefit ratio be achieved by establishing specific guidelines. Key considerations are which chemotherapeutic agent use, adjustment dosages timing relation administration chemotherapy.We have reviewed available...
Circulating endothelial cells (CEC) and progenitor (CEP) play an important role in tissue neovascularization. In human tumours, these may have clinical implications as prognostic/predictive factors during antiangiogenic therapy. The lack of a standardized assay for the quantification rare events has lead to wide variation reported ranges CEC CEP. This study aimed develop flow cytometric (FCM) method immunophenotipic detection enumeration healthy population. Peripheral blood samples from 32...
Blood circulating endothelial cells (CECs), with their resting and activated subsets, (rCECs aCECs) progenitors (CEPs) are two extremely rare cell populations that important in tissue vascularization. Their number function modulated diseases involving vascular injury, such as human tumours. Although a consensus on the phenotypic definition of cells, well optimal enumeration technique, is still lacking, clinical studies based assessment these rapidly expanding, analytical methods employed....
Breast cancer therapies are in continuous evolution: From surgery to hormonal therapy, from classical and new combined chemotherapies emerging targeted agents of recent introduction the clinic. The attempt personalize best treatment for each patient is driven by efficacy safety parameters tumor biology investigations markers aggressiveness response treatment. plethora has provided momentum quest better understand not only target mechanisms action, but also behavior. Moreover, how monitor...
Two areas affected by cement plant emissions, in an industrial district of Central Italy, were investigated foraging honeybees (Apis mellifera ligustica) on the return to their hives, as situ biomonitor. The contamination was compared with that a background reference area Apennine Mountains, quite far from sources. At all sites, bee colonies stationary. One hundred seventy-seven compounds belonging class polycyclic aromatic (PACs) positively identified gas chromatographic and mass...
14576 Background: Panitumumab, a fully human monoclonal antibody against EGFR, has demonstrated efficacy in the treatment of metastatic colorectal carcinoma (mCRC). Multiple links have been found between angiogenesis and both EGFR pathway immunoresponse tumors, influencing properties these new anticancer agents with molecular targets. Flow cytometric (FCM) determination circulating endothelial cells (CECs) progenitor (CEPs) proposed to monitor anti-angiogenetic drug activity. We focused on...
14579 Background: A complex cross-talk was discovered between the immunesystem and endothelial cell compartment during process of neovascularization in tumors. Several angiogenic mediators, such as vascular growth factor (VEGF), have a negative impact on dendritic profile, facilitating tumor escape phenomenon. Bevacizumab (the humanized monoclonal antibody against VEGF), found to improve vivo T-cell mediated response metastatic colorectal cancer (mCRC) (Manzoni M, ECCO 2007). We now focused...
e13103 Background: Several immune-based approaches for treatment of metastatic colorectal cancer (mCRC) are currently under investigation. Aims our study were to grow and characterize tumor cells (TC) obtained from mCRC patients, investigate their susceptibility autologous natural killer (NK) cell recognition killing in vitro. Methods: Tumor samples peripheral blood mononuclear 10 patients undergoing surgery collected. Establishment TC lines that representative the original could be expanded...
14527 Background: Bevacizumab (BEV)-based therapy has improved the outcome of pts with metastatic colorectal cancer (mCRC). As for other antiangiogenetic agents, efficacy this drug is difficult to monitor in clinical setting, using traditional endpoints. Flow cytometric (FCM) evaluation circulating endothelial cells (CECs) and their progenitors (CEPs) been proposed as a surrogate biological marker activity different drugs. We have recently shown that mCRC pts, CECs CEPs are increased by...